Targeting pancreatic cancer with natural compounds: molecular mechanisms, preclinical evidence, clinical perspectives, and limitations
Alberto Orta, Miguel Angel Hidalgo-Leon, Carlos Lacalle-Gonzalez, Miriam M. Rodriguez de Lope, Lara Sanz-Criado, Jesus Garcia-Foncillas, Javier Martinez-Useros · 2026
Read Targeting pancreatic cancer with natural compounds: molecular mechanisms, preclinical evidence, clinical perspectives, and limitations by Alberto Orta, Miguel Angel Hidalgo-Leon, Carlos Lacalle-Gonzalez, Miriam M. Rodriguez de Lope, Lara Sanz-Criado, Jesus Garcia-Foncillas, Javier Martinez-Useros (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13582323.txt.
Description
Alberto Orta and co-authors review natural compounds as candidate weapons against pancreatic cancer, in a 2026 paper. This cancer is among the deadliest, surgery cures only a minority, and standard drugs add modest benefit. Plant and food compounds draw interest because they hit several targets at once and calm inflammation.
In lab and animal studies, selected compounds slowed growth, triggered cancer cell death, curbed spread, and made chemotherapy bite harder. Human use is held back by poor absorption, uneven blood levels, and tangled mechanisms that are hard to pin down. The review weighs the evidence compound by compound and marks what must improve before clinics can take them seriously.
Catalog record
| CREATOR | Alberto Orta, Miguel Angel Hidalgo-Leon, Carlos Lacalle-Gonzalez, Miriam M. Rodriguez de Lope, Lara Sanz-Criado, Jesus Garcia-Foncillas, Javier Martinez-Useros |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 89 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |